The value of PFS36 as a primary endpoint for radiotherapy trials in patients with LACC: individual patient data from the Chinese NCC and validation from 26 RCTs
A significant positive correlation was found between PFS36 and OS at 5 years of follow-up both within patients and across trials. These results suggest that PFS36 is an appropriate endpoint for LACC clinical trials of radiotherapy-based regimens.
Authors
- Xi Yang (ORCID: https://orcid.org/0000-0001-6125-7641)
- Jusheng An (ORCID: https://orcid.org/0000-0001-9603-6849)
- Shuangzheng Jia (ORCID: https://orcid.org/0000-0002-5414-9375)
- Lingying Wu (ORCID: https://orcid.org/0000-0003-3153-7786)
- Yuanyuan Zhang (ORCID: https://orcid.org/0000-0001-8849-0718)
- Wei Li
- Jie Zhu
- Manni Huang (ORCID: https://orcid.org/0000-0002-9158-7518)
- Yong Yang (ORCID: https://orcid.org/0000-0002-4241-9972)
Institutions
- Fujian Medical University (CN)
- University of Electronic Science and Technology of China (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Sichuan Cancer Hospital (CN)
- Union Hospital (CN)
Publication Details
- Journal
- Journal of the National Cancer Center
- Published
- 2025-01-09
- DOI
- https://doi.org/10.1016/j.jncc.2024.08.003
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Cancer Foundation of China